Skip to main content
. 2022 Aug 30;13:998236. doi: 10.3389/fimmu.2022.998236

Figure 6.

Figure 6

Immunotherapy and chemotherapy of cuproptosis-signature. (A) Correlation of CuproptosisScore with seven immunomodulators in gliomas. (B) SubMap analysis for cuproptosis-signature in gliomas. (C) Box plots of estimated IC50 for several chemotherapeutic agents in the high- or low-CuproptosisScore groups. *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001.